Allovir, Inc. financial data

Symbol
ALVR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1100 Winter Street, Waltham, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
ViraCyte, Inc. (to 10/2/2018)
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 805 % -18.4%
Debt-to-equity 25.4 % +13.5%
Return On Equity -104 % -29.9%
Return On Assets -82.9 % -26.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 115 M shares +22.7%
Common Stock, Shares, Outstanding 115 M shares +23%
Entity Public Float 265 M USD +84.9%
Common Stock, Value, Issued 11 K USD +22.2%
Weighted Average Number of Shares Outstanding, Basic 115 M shares +22.9%
Weighted Average Number of Shares Outstanding, Diluted 115 M shares +22.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 115 M USD -4.98%
General and Administrative Expense 46.4 M USD -8.5%
Operating Income (Loss) -189 M USD -10.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -191 M USD -12.8%
Income Tax Expense (Benefit) -126 K USD +52.5%
Net Income (Loss) Attributable to Parent -180 M USD -8.13%
Earnings Per Share, Basic -1.65 USD/shares +15.4%
Earnings Per Share, Diluted -1.65 USD/shares +15.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 86 M USD -25.6%
Cash, Cash Equivalents, and Short-term Investments 141 M USD -30.7%
Assets, Current 141 M USD -33.4%
Property, Plant and Equipment, Net 673 K USD -28.6%
Operating Lease, Right-of-Use Asset 2.11 M USD -92.9%
Other Assets, Noncurrent 122 K USD -80.1%
Assets 144 M USD -40.9%
Accounts Payable, Current 765 K USD -81.5%
Accrued Liabilities, Current 4.6 M USD -62.6%
Liabilities, Current 7.66 M USD -69.3%
Operating Lease, Liability, Noncurrent 16 M USD -37.2%
Liabilities 23.7 M USD -53.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -138 K USD +54.2%
Retained Earnings (Accumulated Deficit) -686 M USD -35.4%
Stockholders' Equity Attributable to Parent 120 M USD -37.8%
Liabilities and Equity 144 M USD -40.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -44.4 M USD -38.2%
Net Cash Provided by (Used in) Financing Activities 70.5 M USD -44.5%
Net Cash Provided by (Used in) Investing Activities 40 M USD -4.13%
Common Stock, Shares Authorized 300 M shares +100%
Common Stock, Shares, Issued 115 M shares +22.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.38 M USD -146%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 86.6 M USD -25.7%
Deferred Tax Assets, Valuation Allowance 181 M USD +120%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 181 M USD +102%
Operating Lease, Liability 18.3 M USD -45.8%
Depreciation 400 K USD -42.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -179 M USD -8.07%
Lessee, Operating Lease, Liability, to be Paid 21.5 M USD -44.9%
Property, Plant and Equipment, Gross 1.92 M USD -0.83%
Operating Lease, Liability, Current 2.3 M USD -72.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.3 M USD +2.14%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.22 M USD -72.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure -16.2%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.19 M USD -39.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.38 M USD +2.06%
Deferred Tax Assets, Operating Loss Carryforwards 54.1 M USD +477%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -126 K USD +52.5%
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.46 M USD +2.04%
Operating Lease, Payments 6.5 M USD +14%
Additional Paid in Capital 807 M USD +15.2%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 10 K USD
Current Federal Tax Expense (Benefit) -136 K USD +44.7%
Depreciation, Depletion and Amortization 398 K USD -45%
Deferred Tax Assets, Net of Valuation Allowance 500 K USD -93.3%
Share-based Payment Arrangement, Expense 35.8 M USD -12.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%